These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 12838275

  • 1. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia.
    Das M, Saikia TK, Advani SH, Parikh PM, Tawde S.
    Bone Marrow Transplant; 2003 Jul; 32(2):125-9. PubMed ID: 12838275
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

  • 4. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S.
    Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
    Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, Freund M, Casper J.
    Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
    [Abstract] [Full Text] [Related]

  • 8. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ.
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
    Krejci M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z, Dvorakova D, Lengerova M, Horky O, Koristek Z, Dolezal T, Vorlicek J.
    Bone Marrow Transplant; 2006 Oct; 38(7):483-91. PubMed ID: 16980996
    [Abstract] [Full Text] [Related]

  • 10. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

  • 11. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W, Cooperative German Transplant Study Group.
    J Clin Oncol; 2003 Jul 15; 21(14):2747-53. PubMed ID: 12860954
    [Abstract] [Full Text] [Related]

  • 12. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan 15; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 13. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
    Basara N, Roemer E, Kraut L, Guenzelmann S, Schmetzer B, Kiehl MG, Fauser AA.
    Bone Marrow Transplant; 2002 Nov 15; 30(10):651-9. PubMed ID: 12420203
    [Abstract] [Full Text] [Related]

  • 14. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
    Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C, Schwerdtfeger R, Kolb HJ.
    Bone Marrow Transplant; 2004 Dec 15; 34(12):1083-8. PubMed ID: 15489879
    [Abstract] [Full Text] [Related]

  • 15. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR, Chen YH, Han W, Wang Y.
    Biol Blood Marrow Transplant; 2011 May 15; 17(5):649-56. PubMed ID: 20691800
    [Abstract] [Full Text] [Related]

  • 16. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H, Yu-Hong C, Jing-Zhi W, Yao C, Xiao-Hui Z, Hong-Xia S, Dao-Pei L.
    Ann Med; 2008 May 15; 40(6):444-55. PubMed ID: 18608121
    [Abstract] [Full Text] [Related]

  • 17. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
    Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, Kojima R, Kishi Y, Kim SW, Ueyama J, Miyakoshi S, Tanosaki R, Morinaga S, Mori S, Heike Y, Muto Y, Masuo S, Taniguchi S, Takaue Y.
    Bone Marrow Transplant; 2004 Apr 15; 33(7):697-702. PubMed ID: 14755317
    [Abstract] [Full Text] [Related]

  • 18. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.
    Vnitr Lek; 2006 Dec 15; 52(12):1172-80. PubMed ID: 17299910
    [Abstract] [Full Text] [Related]

  • 19. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Kornblit B, Masmas T, Madsen HO, Ryder LP, Svejgaard A, Jakobsen B, Sengeløv H, Olesen G, Heilmann C, Dickmeiss E, Petersen SL, Vindeløv L.
    Bone Marrow Transplant; 2008 May 15; 41(10):851-9. PubMed ID: 18246114
    [Abstract] [Full Text] [Related]

  • 20. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.
    Ai Zheng; 2004 Apr 15; 23(4):426-9. PubMed ID: 15087032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.